Latest news with #ZacksS&P500
Yahoo
a day ago
- Business
- Yahoo
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the most searched-for stocks on lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this world's largest biotech drugmaker have returned +6.5%, compared to the Zacks S&P 500 composite's +0.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 1.3%. The key question now is: What could be the stock's future direction? Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision. Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings. We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Amgen is expected to post earnings of $5.21 per share for the current quarter, representing a year-over-year change of +4.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -0%. For the current fiscal year, the consensus earnings estimate of $20.82 points to a change of +4.9% from the prior year. Over the last 30 days, this estimate has changed +0.2%. For the next fiscal year, the consensus earnings estimate of $21.29 indicates a change of +2.2% from what Amgen is expected to report a year ago. Over the past month, the estimate has changed +0.3%. Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Amgen is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS estimate: Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial. In the case of Amgen, the consensus sales estimate of $8.86 billion for the current quarter points to a year-over-year change of +5.6%. The $35.22 billion and $35.78 billion estimates for the current and next fiscal years indicate changes of +5.4% and +1.6%, respectively. Amgen reported revenues of $8.15 billion in the last reported quarter, representing a year-over-year change of +9.4%. EPS of $4.9 for the same period compares with $3.96 a year ago. Compared to the Zacks Consensus Estimate of $7.95 billion, the reported revenues represent a surprise of +2.47%. The EPS surprise was +17.79%. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period. Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects. While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price. As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued. Amgen is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade. The facts discussed here and much other information on might help determine whether or not it's worthwhile paying attention to the market buzz about Amgen. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
3 days ago
- Business
- Yahoo
Countdown to TD SYNNEX (SNX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect TD SYNNEX (SNX) to post quarterly earnings of $2.69 per share in its upcoming report, which indicates a year-over-year decline of 1.5%. Revenues are expected to be $14.32 billion, up 2.7% from the year-ago quarter. Over the last 30 days, there has been an upward revision of 1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding. Given this perspective, it's time to examine the average forecasts of specific TD SYNNEX metrics that are routinely monitored and predicted by Wall Street analysts. Analysts' assessment points toward 'Revenue- Americas' reaching $8.74 billion. The estimate indicates a change of +2.2% from the prior-year quarter. According to the collective judgment of analysts, 'Revenue- Europe' should come in at $4.54 billion. The estimate indicates a change of +2.6% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Revenue- Asia-Pacific and Japan' of $1.03 billion. The estimate indicates a year-over-year change of +6.4%.View all Key Company Metrics for TD SYNNEX here>>>Shares of TD SYNNEX have demonstrated returns of +1.3% over the past month compared to the Zacks S&P 500 composite's +0.6% change. With a Zacks Rank #3 (Hold), SNX is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report TD SYNNEX Corporation (SNX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Compared to Estimates, Korn/Ferry (KFY) Q4 Earnings: A Look at Key Metrics
Korn/Ferry (KFY) reported $712.05 million in revenue for the quarter ended April 2025, representing a year-over-year increase of 3.1%. EPS of $1.32 for the same period compares to $1.26 a year ago. The reported revenue represents a surprise of +3.35% over the Zacks Consensus Estimate of $688.94 million. With the consensus EPS estimate being $1.26, the EPS surprise was +4.76%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Korn/Ferry performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Fee Revenue- Total Executive search: $227 million versus $206.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +14.2% change. Fee Revenue: $712.05 million compared to the $688.94 million average estimate based on two analysts. The reported number represents a change of +3.1% year over year. Fee Revenue- Digital: $91.63 million versus the two-analyst average estimate of $91.65 million. The reported number represents a year-over-year change of +0.4%. Fee Revenue- Consulting: $169.36 million versus $167.62 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7% change. View all Key Company Metrics for Korn/Ferry here>>>Shares of Korn/Ferry have returned -3.3% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Korn/Ferry International (KFY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
GMS (GMS) Reports Q4 Earnings: What Key Metrics Have to Say
GMS (GMS) reported $1.33 billion in revenue for the quarter ended April 2025, representing a year-over-year decline of 5.6%. EPS of $1.29 for the same period compares to $1.93 a year ago. The reported revenue represents a surprise of +2.81% over the Zacks Consensus Estimate of $1.3 billion. With the consensus EPS estimate being $1.15, the EPS surprise was +12.17%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how GMS performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic net sales - Wallboard: -12.5% versus -15.3% estimated by two analysts on average. Organic net sales - Ceilings: 2.9% compared to the -0.9% average estimate based on two analysts. Organic net sales: -9.7% compared to the -11.5% average estimate based on two analysts. Organic net sales - Other product/Complementary products: -7.3% versus -4.1% estimated by two analysts on average. Organic net sales - Steel framing: -17.9% versus the two-analyst average estimate of -23.4%. View all Key Company Metrics for GMS here>>>Shares of GMS have returned -2.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GMS Inc. (GMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Gear Up for AeroVironment (AVAV) Q4 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect AeroVironment (AVAV) to post quarterly earnings of $1.44 per share in its upcoming report, which indicates a year-over-year increase of 234.9%. Revenues are expected to be $243.67 million, up 23.7% from the year-ago quarter. Over the last 30 days, there has been a downward revision of 21.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. That said, let's delve into the average estimates of some AeroVironment metrics that Wall Street analysts commonly model and monitor. Analysts forecast 'Revenue- Product Sales' to reach $198.61 million. The estimate indicates a year-over-year change of +20.7%. According to the collective judgment of analysts, 'Revenue- Loitering Munitions Systems (LMS)' should come in at $133.09 million. The estimate suggests a change of +80.4% year over year. The average prediction of analysts places 'Revenue- Contract Services' at $45.41 million. The estimate indicates a year-over-year change of +40.2%. It is projected by analysts that the 'Revenue- MacCready Works (MW)' will reach $19.93 million. The estimate indicates a change of +2.3% from the prior-year quarter. The combined assessment of analysts suggests that 'Gross margin- Contract services' will likely reach $15.12 million. The estimate is in contrast to the year-ago figure of $11.08 million. The consensus among analysts is that 'Gross margin- Product sales' will reach $81.93 million. The estimate is in contrast to the year-ago figure of $64.55 all Key Company Metrics for AeroVironment here>>>Over the past month, AeroVironment shares have recorded returns of +11.5% versus the Zacks S&P 500 composite's +0.6% change. Based on its Zacks Rank #3 (Hold), AVAV will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AeroVironment, Inc. (AVAV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
